Hale G - Search Results

1

Prophylactic use of an antilymphocyte monoclonal antibody following renal transplantation: a randomized controlled trial.

Friend PJ, Calne RY, Hale G, Waldmann H, Evans DB, Rolles K, Thiru S, Gore S. Friend PJ, et al. Among authors: hale g. Transplant Proc. 1987 Feb;19(1 Pt 3):1898-900. Transplant Proc. 1987. PMID: 3079058 Clinical Trial. No abstract available.

2

Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody.

Friend PJ, Rebello P, Oliveira D, Manna V, Cobbold SP, Hale G, Jamieson NV, Jamieson I, Calne RY, Harris DT, et al. Friend PJ, et al. Among authors: hale g. Transplant Proc. 1995 Feb;27(1):869-70. Transplant Proc. 1995. PMID: 7879212 Clinical Trial. No abstract available.

3

Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.

Calne R, Moffatt SD, Friend PJ, Jamieson NV, Bradley JA, Hale G, Firth J, Bradley J, Smith KG, Waldmann H. Calne R, et al. Among authors: hale g. Transplantation. 1999 Nov 27;68(10):1613-6. doi: 10.1097/00007890-199911270-00032. Transplantation. 1999. PMID: 10589966 Clinical Trial.

4

Reversal of allograft rejection using the monoclonal antibody, Campath-1G.

Friend PJ, Waldmann H, Hale G, Cobbold S, Rebello P, Thiru S, Jamieson NV, Johnston PS, Calne RY. Friend PJ, et al. Among authors: hale g. Transplant Proc. 1991 Aug;23(4):2253-4. Transplant Proc. 1991. PMID: 1908152 No abstract available.

5

Campath-1M--prophylactic use after kidney transplantation. A randomized controlled clinical trial.

Friend PJ, Hale G, Waldmann H, Gore S, Thiru S, Joysey V, Evans DB, Calne RY. Friend PJ, et al. Among authors: hale g. Transplantation. 1989 Aug;48(2):248-53. doi: 10.1097/00007890-198908000-00013. Transplantation. 1989. PMID: 2667209 Clinical Trial.

6

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.

Hale G, Cobbold S, Waldmann H. Hale G, et al. Transplantation. 1988 Apr;45(4):753-9. doi: 10.1097/00007890-198804000-00018. Transplantation. 1988. PMID: 3282358

7

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.

Hale G, Waldmann H. Hale G, et al. J Hematother. 1994 Spring;3(1):15-31. doi: 10.1089/scd.1.1994.3.15. J Hematother. 1994. PMID: 7922004 Clinical Trial.

8

Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.

Hale G, Waldmann H. Hale G, et al. Bone Marrow Transplant. 1994 May;13(5):597-611. Bone Marrow Transplant. 1994. PMID: 8054913

9

Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.

Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H. Lockwood CM, et al. Among authors: hale g. Lancet. 1993 Jun 26;341(8861):1620-2. doi: 10.1016/0140-6736(93)90759-a. Lancet. 1993. PMID: 8099991

10

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.

Hale G, Waldmann H. Hale G, et al. Bone Marrow Transplant. 1996 Mar;17(3):305-8. Bone Marrow Transplant. 1996. PMID: 8704678

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

755 results

Search Page

Filters